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Respiratory failure is an unavoidable event in the natural history of some neuromuscular dis-
eases, while appearing very infrequently in others. In some cases, such as Pompe disease, res-
piratory failure progresses more rapidly than motor impairment, sometimes being the onset
event. Home mechanical ventilation improves survival and quality of life of these patients,
with a reduction in healthcare costs. Therefore, pulmonologists must improve their skills in or-
der to play a more relevant role in the care of these patients. The aim of this statement is to
provide pulmonologists with some simple information in order for them to fulfil their role of
primary caregiver, enabling appropriate and rapid diagnosis and treatment.
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The therapeutic approach to neuromuscular disease (NMD),
including management of respiratory problems, has
recently changed. Over the last decades, respiratory de-
partments dealing with respiratory complications of NMD
are increasing, facing the challenges of caring these com-
plex patients. Nevertheless, a recent Italian survey showed
that diagnosis, respiratory care, provision of information on
respiratory complications and end of life decisions is still
insufficient and needs to be improved.1
In this frame, Pompe disease has a specific relevance.
The low prevalence of Pompe disease, prevents established
experience and increases the risk of underestimating the
severity of respiratory problems, with consequent thera-
peutic delays.2 At difference with other NMD respiratory
failure (RF) progresses more rapidly than motion deficit and
defines the onset of the disease (Table 1).
This review does not add any new information to present
knowledge but, due to the above need, aims to provide basic
information to pulmonologists in order to improve their
therapeutic role, and to perform a correct diagnosis and
prompt treatment of Pompe Disease. In details the present
experts’ opinion claims the need to include always NMD
(including Pompe disease) in evaluating symptoms, signs and
functional results leading a patient to the pulmonologist.Forms and characteristics of Pompe disease
Pompe disease, also referred to as acid maltase deficiency
or glycogen storage disease type II, is a rare, progressive,
autosomal recessive disorder caused by a genetic defect in
acid a-glucosidase gene. This mutation is responsible for the
lack of an enzyme called acid alpha-glucosidase (GAA). The
GAA gene is highly pleomorphic; 289 sequence variationshave been reported to date, including 197 proven patho-
genic mutations.3 Different mutations in the GAA gene are
responsible for the large variability of onset age and disease
severity. The lack of GAA, excessive amounts of lysosomal
glycogen accumulate in the body leading to muscle damage
including respiratory, with related clinical signs and symp-
toms of RF and skeletal muscle weakness. Overall incidence
ranges from 1 in 33,000 to 1 in 300,000, depending on
geographic region.4 The clinical manifestations range from
rapidly progressive early onset to slowly progressive late
onset disease.5 Classic early-onset Pompe disease more
often presents in the first month of life with hypotonia,
generalised muscle weakness, cardiomegaly and hypertro-
phic cardiomyopathy, feeding difficulties, failure to thrive,
respiratory distress, and hearing loss. It commonly results in
death in the first year of life from progressive left ventric-
ular outflow obstruction. The non-classic variant of
infantile-onset Pompe disease usually presents within the
first year of life with motor problems and/or slowly pro-
gressive muscle weakness, typically resulting in death from
ventilatory failure in early childhood. Cardiomegaly can
occur, but heart disease is not a major source of morbidity.
Late-onset (i.e., childhood, juvenile, and adult-onset)
Pompe disease is characterised by proximal muscle weak-
ness and RF without cardiac involvement. The onset can be
as early as on the first or as late as on the sixth decade. On
occasion the so called “juvenile-onset” or mild variant cases
may present prior to 12 months. In late-onset form, the
early manifestations are usually progressive muscle weak-
ness and/or RF.5 Independent of acute onset, progressive
respiratory dysfunction develops in 70% of patients with a
mean reduction in vital capacity (VC) ranging 0.9e4.5%.4,6,7
Respiratory failure is usually cause of significant morbidity
and mortality, the likelihood of needing mechanical venti-
lation (MV) increasing by an average of 8% each year
following diagnosis.5
Table 1 Probability of respiratory failure onset in neuromuscular diseases and conditions/causes of dyspnoea grouped ac-
cording to physiological mechanisms.
 Inevitable
e Duchenne’s muscular dystrophy (DMD)
e Type I spinal muscular atrophy (Type I SMA)
e Motor Neuron Disease or Amyotrophic Lateral Sclerosis (MND-ALS)
 Frequent
e Limb-Girdle muscular dystrophy type 2C, 2D, 2F, 2I
e Nemaline myopathy
e Intermediate spinal muscular atrophy
e Acid Maltase deficiency (Pompe disease)
e Myotubular myopathy
e Ullrich congenital muscular dystrophy
e Congenital myasthenia
e Congenital myotonic dystrophy
 Occasional
e Emery-Dreifuss dystrophy, Becker muscular dystrophy
e Bethlem myopathy, Minicore and Central Core myopathy
 Rare
e Facioscapulohumeral muscular dystrophy
e Mitochondrial myopathy
e Limb-Girdle muscular dystrophy type 1, 2A, B, G, H,
e Oculopharyngeal muscular dystrophy
 Increased respiratory drive
e Interstitial disease
e Pleural effusion
e Cardiovascular pulmonary diseases
e Cardiac decompensation
e Obstructive pulmonary disease
e Compromised muscular pump (NMD)
e Anaemia
e Metabolic acidosis
e Pregnancy
e Psychological factors
 Compromised mechanical ventilation
e Acute and chronic airway obstruction
e Muscular debility (NMD)
e Kyphoscoliosis
e Obesity
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pulmonologist and neurologist
The Respiratory approach consists of a dedicated clinic,
direct fast trach hospital admission and home tele-support
when necessary.1,2 Patients are referred by general prac-
titioners, pediatricians, neurological centres where diag-
nosis has been ascertained and by local associations of
patients and their caregivers in a program of dedicated
outpatient lung function follow-up screening.1,2 Anthropo-
metrics, nutritional status, Arterial blood gases (ABGs),
dynamic and static lung volumes in sitting and supine po-
sition, respiratory muscle function, cardiorespiratory
monitoring, polisonnigraphy, general clinical disability
state by a clinical interview is usually proposed.1,2
In Pompe disease, MV is often required during an episode
of acute RF (ARF) without any previous diagnosis of respi-
ratory problems. Consequently, those patients require
prompt, accurate and frequent respiratory assessments in
order to prevent potential catastrophic situations.8
Diagnosis of respiratory impairment
Respiratory defects associated with Pompe Disease are
characterised by different patterns of clinical and func-
tional onset.
Patterns of clinical onset
Dyspnoea
Dyspnoea is “a subjective symptom of breathing discomfort
that consists of qualitatively distinct sensations that vary in
intensity. It is generally caused by the interaction ofphysiological, psychological, social, and environmental
factors and can cause secondary physiological and behav-
ioural responses”.9 The onset of dyspnoea is caused by
multiple complex mechanisms. In particular, the increased
chemoreceptorial activation in response to hypercapnia
and at a lesser degree to hypoxaemia promotes air hunger.
The feeling of increased inspiratory effort is an integral
component of exertional dyspnoea. Finally, the neuro-
mechanical theory of dyspnoea states that the symptom
arises when there is a disparity between the central reflex
drive and the simultaneous afferent feedback from a
multitude of peripheral sensory receptors throughout the
respiratory system. The feedback system provides infor-
mation about the extent and appropriateness of the me-
chanical response to central drive.10 Possible causes and
mechanisms of dyspnoea must be considered for the diag-
nosis of such symptom. From a clinical perspective there
are two categories of patients suffering from dyspnoea:
patients showing dyspnoea as the onset symptom and
therefore the cause has to be determined; and patients
with known cardiovascular, respiratory, or NMD. In the first
case it is important to understand the driving pathology; in
the second case it is necessary to understand whether there
is worsening of the known pathology or the onset of addi-
tional problems. In patients with a recent history of dysp-
noea, history and physical examination are fundamental for
the diagnosis. In fact, functional tests or biomarkers cannot
be universally used to measure dyspnoea. Specific tests
such as spirometry, D-Dimer, brain natriuretic peptide and
ABG have diagnostic relevance only in specific situations.
Dyspnoea relief is an important goal in the treatment of all
diseases and there are reliable instruments available to
measure its severity in a reproducible way. Daily activities
and stress tests can both be used as stimuli to evaluate
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include the Medical Research Council Breathlessness Scale
(MRC), the Baseline and Transition Dyspnoea Index (BDI,
TDI), the Dyspnoea variable in the Chronic Respiratory
Questionnaire (CRQ), the modified Borg Scale and the Visual
Analogue Scale (VAS).11 Dyspnoea severity should be peri-
odically measured as a standard outcome in treatment of
respiratory diseases. In addition to symptom intensity, pa-
tients’ description of their respiratory discomfort can be
helpful to understand the underlying physiopathologic
mechanisms.9 (Fig. 1).
Respiratory failure
Muscular components of the respiratory system are: (1)
Inspiratory muscles contributing to ventilation; (2) Expira-
tory muscles performing forced expiration and expulsive
stress such as cough; (3) Bulbar muscles protecting airways
from inhalation. Patients usually experience progressive
weakening of muscles and an increased elastic load induced
by reduced pulmonary and thoracic compliance. As a
consequence, they undergo a progressive VC decline and
increased respiratory workload. Rapid shallow breathing
can be associated with an increased respiratory workload
leading to the development of chronic micro-atelectasis
and reduced pulmonary and thoracic compliance.12 Effec-
tive cough requires deep inspiration followed by glottis
closure and appropriate respiratory muscle strength to
generate sufficient intra-thoracic pressure and obtain high
expiratory flows. Expiratory muscle weakness combined
with reduced pulmonary insufflation prevents effective
cough and airway clearance with related increased risk of
pneumonia and atelectasis. Weakness of bulbar muscles
(facial and laryngeal) can alter the ability to speak, swal-
low, and remove airway secretions, increasing the risk of
inhalation. In rapidly progressing disease as Pompe disease,
ARF can be the earliest symptom. Although in slowly pro-
gressing forms of the disease respiratory muscle weakness
has a critical role, also other factors can contribute to the
onset of ARF. These include infections of the airways,
pneumonia, atelectasis, heart failure, respiratory depres-
sant drug abuse, inhalation and pneumothorax.Dyspnoea
• Orthophnoea
• Stress dyspnoea
• Resting dyspnoea
• Lung Function
• VC in clinostatism
• Respiratory muscle function 
Normal
Re-evaluate later
Alterations
• Arterial Blood Gases
• Cough Peak Flow
• Sleep Study
Confirmation of suspected 
NMD
Figure 1 Dyspnoea pattern.There is evidence of sleep respiratory disorders in pa-
tients with Pompe disease.13e16 Diagnosis of sleep respira-
tory disorders requires suspicion and polygraphic/
polysomonographic recording. As in other NMD, hypo-
ventilation during the REM phase seems to be the most
common respiratory alteration in Pompe disease. Sleep res-
piratory disorders are present in 48% of the patients, and 92%
of those are characterised by diaphragmatic weakness.15
Occasional observations also suggest the possibility of
obstructive sleep apnoea.17 As in other NMD, various factors
contribute to the onset of obstructive sleep apnoea. In
particular, weakness of the dilator muscles of the pharynx
causes increased upper airway resistance especially in the
REM phase, which is characterised by profound muscular
atony.18 Macroglossia, as well, can predispose to obstructive
sleep apnoea.17 Indications for polygraphic/polysomno-
graphic recordings during sleep are reported in Fig. 2.
Fig. 3 shows a diagnostic flow chart which can be used in
order to confirm the diagnosis of late-onset Pompe Disease,
based on different dysfunctional patterns at the onset of
respiratory impairment. Diagnostic strategies according to
different conditions are also described.
Respiratory follow-up
Follow-up is important for early diagnosis, prevention and a
timely and appropriate treatment of pulmonary complica-
tions. It should change according to the severity and rate of
pulmonary function deterioration. In recent years follow-up
has been standardised by recommendations and guidelines
for each specific NMD.19e21 Based on these guidelines, we
propose a follow-up model which identifies three different
patient categories:
 Patients with rapidly progressive disease. Despite
adult-onset Pompe disease usually shows a slow pro-
gression, a subgroup of patients can be also included in
this group due to the possibility of developing ARF.
Follow-up for these patients is shown in Table 2.
 Patients with slowly progressive disease: evaluations
should be performed every 6e12 months.
 Patients on long-termNPPV: follow-up is shown inTable 3.
Management of patients with progressive
chronic respiratory failure
The management of patients with chronic respiratory fail-
ure (CRF) is essentially based on the administration of long-
term Home Mechanical Ventilation (HMV), by either inva-
sive or non-invasive route.
Long term non-invasive Positive Pressure
Ventilation (LT-NPPV)
The administration of LT-NPPV requires a positive pressure
ventilator delivering pressurised gas to the lungs through an
interface with the nose or mouth or both.
Mechanism of action: there are three hypotheses.
1. Effect on the chemo-sensitivity of respiratory centre:
when applied overnight, NPPV prevents sleep
Figure 2 Indications to polysomnographic recording: (**) headache, fragmented sleep, sudden arousals, nocturnal apnoea, day
sleepiness, fatigue, strong snoring anamnesis, macroglossia; (#) vital capacity difference between seated and dorsal position >10%;
(x) hypoventilation: SpO2 <90% for at least 5 consecutive minutes (Nadir < 85%) or 30% of the night; increase of PCO2 peak
(>50 mmHg) if measured with capnography. Increase of PaCO2 >45 mmHg with ABG; (B) AHI (Apnoea-hypopnoea index) >15; (
)
substitutive enzymatic treatment (*) SpO2 < 90% for at least 5 consecutive minutes or 30% of the night; (B) 10% or more decrease in
Forced Vital Capacity (FVC) from upright to supine position; (x) SNIP: sniff nasal inspiratory pressure; (**) AHI > 15 E/h; () enzyme
replacement therapy. NPPVZ non-invasive positive pressure ventilation; ERTZ enzyme replacement therapy; CPAPZ continuous
positive airway pressure.
1128 N. Ambrosino et al.hypoventilation and allows the respiratory centre
reset. Respiratory centre sensitivity would be other-
wise reduced due to chronic exposure to hypercapnia.
2. Effect on respiratory muscle fatigue: night NPPV may
restore respiratory muscle strength and endurance.
3. Effect on rib cage-lung expansion: NPPV maintains rib
cage-lung expansion through the insufflation of a tidal
volume higher than the one obtained through sponta-
neous ventilation.22
a) Indications: after all reversible factors (airways in-
fections, cardiac failure, severe electrolyte imbalance,
etc.) have been treated, use of LT-NPPV is indicated by
the following conditions19,20:
1. Symptoms attributable to hypoventilation (such as fa-
tigue, dyspnoea, morning headache) and one of the
following:
2. Physiologic criteria:
1. Significant daytime CO2 retention (PaCO2 >
50 mmHg);
2. Nocturnal oxygen desaturation (SaO2 < 88% for at
least five consecutive minutes);
3. Forced Vital Capacity (FVC) <50% predicted or
Maximal Inspiratory Pressure <60 cm H2O, only for
rapidly progressive disease.
b) the following are considered as conditions reducing the
effectiveness of LT-NPPV22:
1. Severe swallowing disorders with risk of chronic inha-
lation and aspiration pneumonia
2. Insufficient elimination of bronchial secretions despite
the use of manual/mechanical cough assistance
3. Continuous need of HMV (>20 h/day)These are conditions frequently requiring an invasive
application of MV. The combination of LT-NPPV with assisted
coughing techniques or crycothyroid “minitracheostomy”
may avoid tracheostomy-PPV in subjects with severe inability
to cough out airway secretions.23,24
d) Ventilation techniques: While the earliest ventilators
used for LT-NPPV were unsophisticated volume-limited
devices, in recent years manufacturers have developed
a new generation of microprocessor-controlled ventila-
tors that supply both volume- and pressure-limited
modes. Recent ventilation techniques like Pressure
Support Ventilation combine stable minimum ventilation
with greater comfort for the patient. However, there are
no data suggesting that these methods are better than
the others in terms of gas exchange, patient comfort and
patienteventilator interaction.25 There is no consensus
about the interface: nasal masks are more comfortable
for night ventilation while oronasal masks reduce air loss
from mouth and nose. Mouthpieces have been success-
fully used in patients subjected to continuous NPPV.Long-term invasive mechanical ventilation (LT-IMV)
or tracheostomy ventilation
This is recommended when NPPV fails or is contraindicated,
for example, when ventilation support is constantly needed
(>20 h/day), in presence of ineffective cough despite
assistance and when airways cannot be protected.25 Com-
plications are described in Table 4.
Figure 3 In case of “restrictive deficit” pattern the following causes have to be excluded: cardiac decompensation, kypho-
scoliosis, post-surgical (thoracic, cardiac, abdominal), diaphragm paralysis, extreme obesity, old age, fibrothorax and pulmonary
fibrosis. In case of “nocturnal hypoventilation” pattern the following causes have to be excluded: Chronic obstructive pulmonary
disease (COPD), overlap syndrome, obstructive sleep apnoea syndrome (OSAS), cardiac decompensation, kyphoscoliosis, post-
surgical (thoracic, cardiac, abdominal), diaphragm paralysis, extreme obesity, fibrothorax and pulmonary fibrosis. In case of
CRF the following causes have to be excluded: COPD, overlap syndrome, kyphoscoliosis, fibrothorax, pulmonary fibrosis, cardiac
decompensation, post-surgical (thoracic, cardiac, abdominal), diaphragm paralysis and extreme obesity. In case of reduced res-
piratory muscles strength the following causes have to be excluded: COPD, overlap syndrome, kyphoscoliosis, fibrothorax, pul-
monary fibrosis, cardiac decompensation, post-surgical (thoracic, cardiac, abdominal), diaphragm paralysis, neurological disorders
and endocrine disorders. In case of diaphragm elevation the following causes have to be excluded: post-surgical (thoracic, cardiac,
abdominal), diaphragm paralysis, degenerative neurological disorders and endocrine disorders. FEV1Z forced expiratory volume in
1 second; VC Z vital capacity; SEE Z standard errors of the estimate; TLC Z total lung capacity; RV Z residual volume.
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Clinical evolution of patients with progressive CRF is generally
markedbyexacerbationphases triggeredbyairway infections.
They often cause episodes of bronchial secretion encum-
brance requiring manual or mechanical cough assistance.Table 2 Respiratory follow-up for patients with rapidly evolvin
Indicator Frequency
Respiratory signs
and symptoms
3e6 months
Forced vital
capacity (FVC)
3e6 months
Maximal inspiratory
pressure (MIP)
3e6 months
Cough peak expiratory
flow (CPEF)
3e6 months
Blood gas analysis (ABG) 3e6 months
PLSG/CRM In case of:
- Sleep-related symptoms
- Functional thresholds
PLSG Z polysomnography; CRM Z nocturnal cardio-respiratory monitAdditional actions
Infection prophylaxis, including influenza vaccine and
immunisation with anti-pneumococcus vaccine. Table 5
shows suggested interventions for NMD with progressive
CRF.g NMD.
Threshold Operative strategy
Appearance Perform PLSG/CRM
Mandatory NPPV
<40% pred Perform PLSG/CRM
<50 H20 Intensify follow-up
Perform PLSG/CRM
<160 L/min Cough assistance
PaCO2 > 48e50 mmHg Mandatory NPPV
PaCO2 > 48-mmHg SaO2 < 88%
for > 5 consecutive min
Mandatory NPPV
oring.
Table 5 Intervention strategy for patients with progres-
sive chronic respiratory failure.
Intervention Indication
Manual/mechanical
cough assistance
- CPEF < 160 L/min
- FVC < 40% pred
Table 3 Respiratory follow-up for patients subjected to long-term NPPV.
Indicator Frequency Threshold Operative strategy
Respiratory signs
and symptoms
3e6 months Symptom onset/worsening Reset parameters/increment
daily use of NPPV
Vital capacity 3e6 months DY >100e200 mL Reset parameters/increase
daily use of NPPV
Blood gas analysis 3e6 months D[ PaCO2 > 5 mmHg Reset parameters/increase
daily use of NPPV
Cough peak
expiratory flow
3e6 months <160 L/min Cough assistance
MV dependency 3e6 months >18 h/die Consider tracheostomy
Swallowing ability 3e6 months Asphyxia episodes,
frequent respiratory infections
Consider tracheostomy
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Advanced discussion of a treatment plan should be standard
care for Pompe disease patients and their families. Unfor-
tunately, provision of information on respiratory compli-
cations and end of life decisions is still insufficient and
needs to be improved, so that patients and caregivers can
be more active participants in disease management. Only
32.1% of Respiratory Italian Units discussed end-of-life is-
sues and obtained advanced directives from their patients
concerning life support.1 This reveals that not enough effort
is being made to educate Pompe patients on breathing
support options, if they desire to prolong their life and still
continue to stay active socially. When requested and indi-
cated, palliative program includes knowledge and expertise
in home-based end-of-life palliative care aimed at the
improvement of quality of life through better respiratory
symptoms control and pain relief, emotional and spiritual
support and patient education.26
Management of patients with acute respiratory
failure
Acute respiratory failure is more commonly a consequence of
respiratory tract infection in patients with known ventilatory
defect associated with late-onset Pompe disease. Acute
respiratory failure is the most frequent cause of death inde-
pendent of the rate of progression of NMD. Therefore,Table 4 Complications associated with long-term me-
chanical ventilation through tracheostomy.
 Cannula obstruction, reinsertion difficulties,
accidental removal
 Tracheal stoma infection
 Tracheal decubitus lesion
 Tracheal granuloma
 Tracheomalacia
 Pneumothorax, pneumomediastinum,
subcutaneous emphysema
 Tracheoinnominate fistula
 Tracheoesophageal fistula
 Tracheocutaneous fistulauncompensated hypercapnic ARF represents a critical event
requiring special attention to avoid premature death.27 Even
in case of survival, the general conditions of patients and
their quality of life canworsen as a result of the acute disease
itself and due to its intensive management.
Since an ARF episode can lead to ominous consequences,
early monitoring is fundamental. This includes periodic
check-ups, functional measurements, infections prophylaxis
and training for home management of respiratory problems,
including cough assistance. When hospitalisation is needed,
the preferable location is a Respiratory Intensive Care Units
(RICU). In fact, prolonged ICU stay with invasive MV can be
complicated by hospital infections, aspirations, atelectases,
thromboembolism, muscular/articular contractures and in-
juries, and ulcers.28 Therefore, when the patient experi-
ences ARF, themedical approach must be fast and effective,
preferably using non-invasive techniques, and must include
both rehabilitation and cure.
Management of ARF includes the following measures:
 Mechanical ventilation, preferably NPPV to assist
inspiratory muscles.- MEP < 50 H20
Nocturnal NPPV - PaCO2 > 48e50 mmHg
- Signs and symptoms of
sleep-related hypoventilation
Nocturnal NPPV - Treatment auto-extension
- Speaking difficulty during
normal breath
- Swallowing difficulty during
normal breath
Tracheostomy - Patient preference
- NPPV failure
- Cough assistance failure
- Severe dysphagia
MEP: maximal expiratory pressure;
CPEF: cough peak expiratory flow; FVC: forced vital capacity.
Table 6 Outcome measures in Pompe disease.
Stage 1 e Improvement/stabilization of vital
capacity (% expected) and respiratory
muscle strength tests (MIP/MEP)
Stage 2 e Improvement/stabilization of vital
capacity (% predicted) and respiratory
muscle strength tests (MIP/MEP)
e Reduction of Stress Dyspnoea
e Increased PCEF (manual/mechanical
assistance)
e Reduction in number, frequency and
duration of pulmonary infections
(bronchopneumonia
episodes or atelectasis proved with
radiologic examination)
e Reduction of exacerbations that
require antobiotics
e Sleep quality improvement
e Life quality improvement
Stage 3 e Reduction in number, frequency and
duration of pulmonary infections and
bronchoaspirations
e Reduced ventilation hours (<8/day)
e Change of the type of ventilation
assistance (from controlled to
assisted)
e Tracheostomy removal
e Improved ability in common daily
activities after MV
e Sleep quality improvement
e Life quality improvement
The role of respiratory management of Pompe disease 1131 Optimal oxygen supplement when required (maintain
saturation between 92 and 94% and monitor PaCO2 and
pH)
 Airway secretion clearance through cough assist devices
and other physiotherapeutic techniques.
 Endotracheal intubation, only in severe cases
 Nutritional therapy to reduce aspiration risk
 Physiotherapy to reduce joint problems
 Aggressive infection treatment
Specific therapies against neuromuscular defects should
not be suspended (e.g., substitutive enzymatic therapy).
Cough assist devices and respiratory physiotherapy may
help airway clearance in patients with expiratory muscular
weakness. NPPV is used both as an alternative to endo-
tracheal intubation and/or to facilitate weaning.29 More-
over, a mini-tracheotomy associated with NPPV can also
enhance airway clearance during an acute infection.
The following procedures can worsen spontaneous
breathing ability and should be avoided:
 Use of sedatives, unless strictly necessary
 Use of paralytic agents
 Prolonged immobility without passive patient
mobilisation
 Intubation and controlled MV
 Prolonged dorsal position (risk of aspirations and aspi-
ration pneumonia)
Enzyme replacement therapy with Myozymetm (a-alglu-
cosidase) is commercially available. This represents the
only available etiologic therapy for this NMD. The substi-
tutive enzyme is industrially produced through biotechno-
logical processes and administered through intravenous
infusion. This therapy can be effective in preventing Pompe
disease progression in patients where the disease has a late
onset.30e33
Outcome measures for late-onset Pompe
disease
Patients with late-onset Pompe disease are classified as
pre-symptomatic, symptomatic and severe.27,31,34 This
classification reflects the phenotypic variability of the dis-
ease and represents the starting point for the classification
of respiratory outcome measures. They are described in
Table 6 and discussed below:
 First stage: proximal muscle weakness or upright and
supine FVC reduction.
 Second stage: limb muscle weakness or upright and
supine FVC reduction or difficulty in carrying out normal
activities; possible use of NPPV.
 Third stage: loss of ambulation, NPPV dependency and/
or need of invasive ventilation (tracheotomy).
The substitutive enzymatic therapy is indicated at all
stages but has to be re-evaluated at the third stage after
the first year of treatment. Recent studies reported a po-
tential effect of substitutive enzymatic therapy even in
extremely severe and long-lasting forms of the disease.35Conclusions
Caring for Pompe disease patients with respiratory com-
plications has a major impact on their life-expectancy and
quality of life. Therefore, the diagnostic-therapeutic role
of pulmonologist is fundamental for those patients.
However, in order for this role to be completely effective,
guidelines for a uniformed clinical approach must be
implemented and clinicians have to operate in specialised
multidisciplinary centres. In particular, the combined and
coordinated approach between pulmonologists and neu-
rologists is essential in order to manage this disease
properly. Despite this article focuses on the conditions of
the Italian health care system we feel that these
conclusion can be transferable to other countries. Indeed
the management of patients requiring long term me-
chanical ventilation poses similar problems to different
Health systems as outlined by a recent European
Survey.36,37Conflict of interest
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